ITIL-168 in Advanced Melanoma

Stopped early · Phase 2

Conditions studied: Advanced Cutaneous Melanoma

In brief

DELTA-1 is a phase 2 clinical trial to evaluate the efficacy and safety of ITIL-168 in adult subjects with advanced melanoma who have previously been treated with a PD-1 inhibitor. ITIL-168 is a cell therapy derived from a patient's own tumor-infiltrating immune cells (lymphocytes; TILs).

Key facts

Study ID
NCT05050006
Run by
Instil Bio
People needed
29
Starts
2021-10-07
Expected to finish
2023-02-27
Last updated by the study team
2024-04-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.